Antiplatelet Therapy to Prevent Cardiovascular Events and Mortality in Patients With Intermittent Claudication

    loading  Checking for direct PDF access through Ovid

Abstract

Clinical Question

Do antiplatelet therapies reduce risk of all-cause mortality, cardiovascular disease (CVD) mortality, and cardiovascular events in patients with intermittent claudication? Which antiplatelet is most strongly associated with a reduced risk of all-cause and CVD mortality?

Bottom Line

In patients with intermittent claudication, antiplatelet therapies are associated with lower all-cause and CVD mortality compared with placebo. Compared with all antiplatelet therapies, the strongest evidence exists for thienopyridines, such as clopidogrel.

Related Topics

    loading  Loading Related Articles